Clinical Trials Logo

CD20+ Aggressive B-Cell Lymphoma clinical trials

View clinical trials related to CD20+ Aggressive B-Cell Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01478542 Completed - Clinical trials for CD20+ Aggressive B-Cell Lymphoma

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

OPTIMAL>60
Start date: November 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to improve the outcome of elderly patients with CD20-Aggressive B-Cell Lymphoma and to reduce the toxicity of standard used Immuno-Chemotherapy by using an optimised schedule of the monoclonal antibody Rituximab, substituting conventional by Liposomal Vincristine and by a PET-guided reduction of therapy in Combination with Vitamin D Substitution.